Fluid Retention in AVANDIA Treated Subjects With Autonomic Neuropathy
This study has been completed.
Information provided by:
First received: January 15, 2007
Last updated: October 15, 2008
Last verified: October 2008
Fluid management study in patients with type 2 diabetes and autonomic neuropathy.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Primary Purpose: Treatment
|Official Title:||A 16-Week, Randomised, Double-Blind, Placebo-Controlled, Single-Centre Study to Investigate Fluid Retention in Insulin-Treated Subjects With Type 2 Diabetes Mellitus and Varying Degrees of Autonomic Neuropathy When Administered Rosiglitazone 4 mg bd|
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by GlaxoSmithKline:
Primary Outcome Measures:
- Change in transcapillary escape rate of L125 albumin following 16 weeks treatment
Secondary Outcome Measures:
- Change in plasma volume, pedal oedema, extracellular fluid volume following 16 weeks treatment.
|Study Start Date:||November 2003|
Drug: AVANDIA (rosiglitazone)
Other Name: AVANDIA (rosiglitazone)
Contacts and Locations